Company: SCLXW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047800
Chunk: 60

Company: Scilex Holding Co
Filing Date: 2025-03-31
Form: 10-K
Item: Item 7
Chunk 60
---
 warrants that we issued to such investor in the February 2024 BDO on March 5, 2024. Pursuant to the Warrant Amendment, the investor agreed to exercise outstanding warrants to purchase an aggregate of 1,764,706 shares of Common Stock in cash at an amended exercise price of $0.59 per share. The gross proceeds to us from such exercise was approximately $1.0 million.

 134

Future Liquidity Needs

We have based our anticipated operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to:

•the costs and expenses associated with our ongoing commercialization efforts for ZTlido, GLOPERBA and ELYXYB;

•the degree of success we experience in commercializing ZTlido, GLOPERBA and ELYXYB;

•the revenue generated by sales of ZTlido, GLOPERBA, ELYXYB and other products that may be approved, if any;

•the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, SP-103 and SP-104;

•the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;

•the costs of manufacturing ZTlido, GLOPERBA, ELYXYB and our product candidates;

•the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements;

•our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;

•the extent to which ZTlido, GLOPERBA, ELYXYB or any of our product candidates, if approved for commercialization, is adopted by the physician community;

•our need to expand our research and development activities;

•the costs of acquiring, licensing or investing in businesses, product candidates and technologies;

•the effect of competing products and product candidates and other market developments;

•the number and types of future products we develop and commercialize;

•any product liability or other lawsuits related to our products;

•the expenses needed to attract, hire and retain skilled personnel;

•the costs